Womesh Sahadeo, MD
Psychiatry · West Palm Beach, FLNPI 1386625929
Payments from drug & device makers
Across 1,454 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$4K
- AbbVie$4K
- Otsuka America Pharmaceutical, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $11K from 22 others
What the payments were for
- Speaking & faculty fees$1,5505%
- Food & beverage$27,60793%
- Education$4261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 148 | $4,239 |
| AbbVie(2 entities) | 247 | $4,048 |
| Otsuka America Pharmaceutical, Inc. | 150 | $2,926 |
| Teva Pharmaceuticals USA, Inc. | 119 | $2,635 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 111 | $2,541 |
| Takeda Pharmaceuticals U.S.A., Inc. | 144 | $2,401 |
| Sunovion Pharmaceuticals Inc. | 119 | $1,997 |
| Lundbeck LLC | 94 | $1,889 |
| Vanda Pharmaceuticals Inc. | 78 | $1,758 |
| Johnson & Johnson | 53 | $1,056 |
| Neurocrine Biosciences, Inc. | 42 | $1,003 |
| Axsome Therapeutics, Inc. | 24 | $660 |
| Supernus Pharmaceuticals, Inc. | 22 | $501 |
| Merck | 19 | $362 |
| Eisai Inc. | 17 | $301 |
| Idorsia Pharmaceuticals US Inc | 10 | $224 |
| E.r. Squibb & Sons, L.L.C. | 8 | $213 |
| Indivior Inc. | 8 | $207 |
| Corium, LLC | 12 | $197 |
| Shire North American Group Inc | 13 | $134 |
| Adlon Therapeutics L.p. | 5 | $90 |
| Almatica Pharma LLC | 2 | $40 |
| Pfizer | 2 | $39 |
| Orexo US, Inc. | 3 | $38 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,584 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 28 | $197,194 |
| RexultiBrexpiprazole | 94 | $135,498 |
| VraylarCariprazine Hcl | 87 | $131,550 |
| Abilify MaintenaAripiprazole | 34 | $92,645 |
| TrintellixVortioxetine Hydrobromide | 136 | $66,757 |
| LybalviOlanzapine/Samidorphan Malate | 33 | $50,740 |
| Invega SustennaPaliperidone Palmitate | 16 | $49,556 |
| AuvelityDextromethorphan Hbr/Bupropion | 30 | $32,019 |
| CaplytaLumateperone Tosylate | 18 | $29,510 |
| Lurasidone Hcl | 73 | $19,833 |
| FanaptIloperidone | 13 | $18,828 |
| UbrelvyUbrogepant | 12 | $18,592 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 233 | $6,289 |
| Risperidone OdtRisperidone | 13 | $5,643 |
| Alprazolam | 1,192 | $5,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $2,926 | $228,144128 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,635 | $197,19428 claims |
| AbbVieVraylar, Ubrelvy | $4,048 | $150,14299 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $2,401 | $66,757136 claims |
| Alkermes, Inc.Lybalvi | $4,239 | $50,74033 claims |
| Johnson & JohnsonInvega Sustenna | $1,056 | $49,55616 claims |
| Axsome Therapeutics, Inc.Auvelity | $660 | $32,01930 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,541 | $29,51018 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,758 | $18,82813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in West Palm Beach
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.